Stuart J Menn1, Ronghua Yang2, Alan Lankford3. 1. Pacific Sleep Medicine Services, Palm Springs, CA. 2. Teva Pharmaceutical Industries Ltd., Frazer, PA. 3. Sleep Disorders Center of Georgia, Atlanta, GA.
Abstract
OBJECTIVE: To evaluate the efficacy and tolerability of armodafinil in patients with excessive sleepiness following mild or moderate closed traumatic brain injury (TBI). DESIGN: Randomized, placebo-controlled, double-blind trial followed by open-label extension. SETTING: 40 US centers. PATIENTS: Adults with closed TBI (N = 117), Glasgow Coma Scale score >8 at time of injury; baseline Epworth Sleepiness Scale (ESS) ≥10; sleep latency <8 minutes on multiple sleep latency test (MSLT); and Clinical Global Impression-Severity of Illness (CGI-S) score ≥4 for excessive sleepiness. INTERVENTION: Patients received armodafinil (50, 150, or 250 mg/day) or placebo for 12 weeks followed by an optional 12-month open-label extension. MEASUREMENTS AND RESULTS: Outcomes included MSLT, ESS, Clinical Global Impression-Change (CGI-C), TBI-Work Instability Scale (TBI-WIS), CGI-S, and tolerability. The study was terminated early due to low enrollment. Patients receiving 250 mg armodafinil showed significant improvement in sleep latency from baseline to final visit versus placebo (+7.2 minutes vs. +2.4 minutes; p = 0.0010). CGI-C ratings were much/ very much improved in approximately 50% of patients receiving 150 and 250 mg armodafinil, compared to 38% on placebo. ESS and TBI-WIS scores were not significantly different between groups. In the open-label extension (N = 49), patients demonstrated gradual improvement in ESS, TBI-WIS, and CGI-S scores up to 48 weeks post-baseline. Armodafinil was generally well tolerated, with headache the most common adverse event in both double-blind and open-label portions. CONCLUSIONS:Armodafinil 250 mg significantly improved sleep latency in patients with excessive sleepiness associated with mild or moderate TBI. Efficacy and tolerability of armodafinil were sustained throughout the open-label extension. TRIAL REGISTRATION: NCT00893789, NCT00983437.
RCT Entities:
OBJECTIVE: To evaluate the efficacy and tolerability of armodafinil in patients with excessive sleepiness following mild or moderate closed traumatic brain injury (TBI). DESIGN: Randomized, placebo-controlled, double-blind trial followed by open-label extension. SETTING: 40 US centers. PATIENTS: Adults with closed TBI (N = 117), Glasgow Coma Scale score >8 at time of injury; baseline Epworth Sleepiness Scale (ESS) ≥10; sleep latency <8 minutes on multiple sleep latency test (MSLT); and Clinical Global Impression-Severity of Illness (CGI-S) score ≥4 for excessive sleepiness. INTERVENTION: Patients received armodafinil (50, 150, or 250 mg/day) or placebo for 12 weeks followed by an optional 12-month open-label extension. MEASUREMENTS AND RESULTS: Outcomes included MSLT, ESS, Clinical Global Impression-Change (CGI-C), TBI-Work Instability Scale (TBI-WIS), CGI-S, and tolerability. The study was terminated early due to low enrollment. Patients receiving 250 mg armodafinil showed significant improvement in sleep latency from baseline to final visit versus placebo (+7.2 minutes vs. +2.4 minutes; p = 0.0010). CGI-C ratings were much/ very much improved in approximately 50% of patients receiving 150 and 250 mg armodafinil, compared to 38% on placebo. ESS and TBI-WIS scores were not significantly different between groups. In the open-label extension (N = 49), patients demonstrated gradual improvement in ESS, TBI-WIS, and CGI-S scores up to 48 weeks post-baseline. Armodafinil was generally well tolerated, with headache the most common adverse event in both double-blind and open-label portions. CONCLUSIONS:Armodafinil 250 mg significantly improved sleep latency in patients with excessive sleepiness associated with mild or moderate TBI. Efficacy and tolerability of armodafinil were sustained throughout the open-label extension. TRIAL REGISTRATION: NCT00893789, NCT00983437.
Authors: Amitabh Jha; Alan Weintraub; Amanda Allshouse; Clare Morey; Chris Cusick; John Kittelson; Cynthia Harrison-Felix; Gale Whiteneck; Don Gerber Journal: J Head Trauma Rehabil Date: 2008 Jan-Feb Impact factor: 2.710
Authors: Maria I Lapid; Karen M Kuntz; Sara S Mason; Jeremiah A Aakre; Emily S Lundt; Walter Kremers; Laura A Allen; Daniel A Drubach; Bradley F Boeve Journal: Dement Geriatr Cogn Disord Date: 2017-04-28 Impact factor: 2.959
Authors: Emerson M Wickwire; David M Schnyer; Anne Germain; Scott G Williams; Christopher J Lettieri; Ashlee B McKeon; Steven M Scharf; Ryan Stocker; Jennifer Albrecht; Neeraj Badjatia; Amy J Markowitz; Geoffrey T Manley Journal: J Neurotrauma Date: 2018-08-24 Impact factor: 5.269
Authors: Emerson M Wickwire; Scott G Williams; Thomas Roth; Vincent F Capaldi; Michael Jaffe; Margaret Moline; Gholam K Motamedi; Gregory W Morgan; Vincent Mysliwiec; Anne Germain; Renee M Pazdan; Reuven Ferziger; Thomas J Balkin; Margaret E MacDonald; Thomas A Macek; Michael R Yochelson; Steven M Scharf; Christopher J Lettieri Journal: Neurotherapeutics Date: 2016-04 Impact factor: 7.620